The sites of the interconnection of the NF-κB, Nrf2 and STAT3 signaling pathways and aberrations in their activation mechanisms make it possible to use them as targets in cancer cells for potential chemotherapeutic compounds. This evidence concerns the gene NFKB1 and cancer.